Botulinum toxin (BT) has been perceived as a lethal threat for many centuries. In the early 1980s, this perception completely changed when BT’s therapeutic potential suddenly became apparent. We wish to give an overview over BT’s mechanisms of action relevant for understanding its therapeutic use. BT’s molecular mode of action includes extracellular binding to glycoprotein structures on cholinergic nerve terminals and intracellular blockade of the acetylcholine secretion. BT affects the spinal stretch reflex by blockade of intrafusal muscle fibres with consecutive reduction of Ia/II afferent signals and muscle tone without affecting muscle strength (reflex inhibition). This mechanism allows for antidystonic effects not only caused by target muscle paresis. BT also blocks efferent autonomic fibres to smooth muscles and to exocrine glands. Direct central nervous system effects are not observed, since BT does not cross the blood-brain barrier and since it is inactivated during its retrograde axonal transport. Indirect central nervous system effects include reflex inhibition, normalisation of reciprocal inhibition, intracortical inhibition and somatosensory evoked potentials. Reduction of formalin-induced pain suggests direct analgesic BT effects possibly mediated by blockade of substance P, glutamate and calcitonin gene-related peptide.

1.
Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Sudhof TC, Niemann H, Jahn R: Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365:160–163.
2.
Ceballos-Baumann AO, Sheean G, Passingham RE, Marsden CD, Brooks DJ: Botulinum toxin does not reverse the cortical dysfunction associated with writer’s cramp: A PET study. Brain 1997;120:571–582.
3.
Cuesta M, Arcaya J, Cano G: Opposite modulation of capsaicin-evoked substance P release by glutamate receptors. Neurochem Int 1999;35:471–478.
4.
Cui M, Aoki R: Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalalgia 2000;20:414.
5.
Cui M, Li Z, You S, Khanijou S, Aoki R: Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing. Arch Pharmacol 2002;365:R17.
6.
Dressler D: Botulinum toxin therapy failure: Causes, evaluation procedures and management strategies. Eur J Neurol 1997;4(suppl 2):S67–S70.
7.
Dressler D: Botulinum Toxin Therapy. Stuttgart, Thieme, 2000.
8.
Dressler D: Dysport produces intrinsically more swallowing problems than Botox: Unexpected results from a conversion factor study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;73:604.
9.
Dressler D, Benecke R: Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003;49:34–38.
10.
Dressler D, Eckert J, Kukowski B, Meyer B: Somatosensory evoked potentials in writer’s cramp: Pathological findings reversed by botulinum toxin therapy. EEG Clin Neurophysiol 1995;94:59P.
11.
Dressler D, Rothwell JC: Electromyographic quantification of the paralysing effect of botulinum toxin. Eur Neurol 2000;43:13–16.
12.
Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E: Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993;113:400–404.
13.
Gilio F, Curra A, Lorenzano C, Modugno N, Manfredi M, Berardelli A: Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol 2000;48:20–26.
14.
Girlanda P, Vita G, Nicolosi C, Milone S, Messina C: Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 1992;55:844–845.
15.
Hagenah R, Benecke R, Wiegand H: Effects of type A botulinum toxin on the cholinergic transmission at spinal Renshaw cells and on the inhibitory action at Ia inhibitory interneurones. Naunyn Schmiedebergs Arch Pharmacol 1977;299:267–272.
16.
Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, Shimizu K: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000;44:106–109.
17.
Kaji R, Kohara N, Katayama M, Kubori T, Mezaki T, Shibasaki H, Kimura J: Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer’s cramp. Muscle Nerve 1995;18:234–235.
18.
Kerner J: Neue Beobachtungen über die in Württemberg so häufig vorfallenden tödlichen Vergiftungen durch den Genuss geräucherter Würste. Tübingen, Osiander, 1820.
19.
Kerner J: Das Fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Stuttgart, Cotta, 1822.
20.
Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE: Distant effects of local injection of botulinum toxin. Muscle Nerve 1987;10:552–555.
21.
Ludlow CL, Hallett M, Sedory SE, Fujita M, Naunton RF: The pathophysiology of spasmodic dysphonia and its modification by botulinum toxin; in Berardelli A, Benecke R, Manfredi M, Marsden CD (eds): Motor Disturbances II. New York, Academic Press, 1990, pp 273–288.
22.
McMahon H, Foran P, Dolly J: Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: Clues to the locus of action. J Biol Chem 1992;267:21338–21343.
23.
Modugno N, Priori A, Berardelli A, Vacca L, Mercuri B, Manfredi M: Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor. Muscle Nerve 1998;21:1701–1705.
24.
Moreno-Lopez B, de la Cruz RR, Pastor AM, Delgado-Garcia JM: Botulinum neurotoxin alters the discharge characteristics of abducens motoneurons in the alert cat. J Neurophysiol 1994;72:2041–2044.
25.
Morris J, Jobling P, Gibbins I: Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001;281:2124–2132.
26.
Olney RK, Aminoff MJ, Gelb DJ, Lowenstein DH: Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988;38:1780–1783.
27.
de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO: Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200–3205.
28.
Priori A, Berardelli A, Mercuri B, Manfredi M: Physiological effects produced by botulinum toxin treatment of upper limb dystonia: Changes in reciprocal inhibition between forearm muscles. Brain 1995;118:801–807.
29.
Purkiss J, Welch M, Doward S, Foster K: Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: Involvement of two distinct mechanisms. Biochem Pharmacol 2000;59:1403–1406.
30.
Rizo J, Sudhof TC: Mechanics of membrane fusion. Nat Struct Biol 1998;5:839–842.
31.
Rosales RL, Arimura K, Takenaga S, Osame M: Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996;19:488–496.
32.
Sanders DB, Massey EW, Buckley EG: Botulinum toxin for blepharospasm: Single-fibre EMG studies. Neurology 1986;36:545–547.
33.
Shone CC, Melling J: Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin: Long-term effects of the neurotoxin on intact cells. Eur J Biochem 1992;207:1009–1016.
34.
Takamizawa K, Iwamori M, Kozaki S, Sakaguchi G, Tanaka R, Takayama H, Nagai Y: TLC immunostaining characterization of Clostridium botulinum type A neurotoxin binding to gangliosides and free fatty acids. FEBS Lett 1986;201:229–232.
35.
Welch MJ, Purkiss JR, Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245–258.
36.
Wiegand H, Erdmann G, Wellhoner HH: 125I-labelled botulinum A neurotoxin: Pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1976;292:161–165.
37.
Yoshida K, Kaji R, Kubori T, Kohara N, Iizuka T, Kimura J: Muscle afferent block for the treatment of oromandibular dystonia. Mov Disord 1998;13:699–705.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.